Daratumumab Medicine 08 December 2020 Extended indication Smouldering multipel myeloom. Therapeutic value No estimate possible yet Total cost € 13,375,943.00 Registration phase Clinical trials Product Active substance Daratumumab Domain Hematology Reason of inclusion Indication extension IND Main indication Multiple Myeloma Extended indication Smouldering multipel myeloom. Current proprietary name Already available biosimilars / generics Proprietary name Darzalex Manufacturer Janssen Portfolio holder Mechanism of action Other, see general comments Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date May 2023 Expected Registration March 2024 Orphan drug Yes Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Fabrikant verwacht registratie in het maart 2024. Dit geneesmiddel is breed uitgesloten, wat betekent dat toekomstige indicaties automatisch in de sluis stromen. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration 1800mg References NCT03301220. Additional remarks Jaar 1: 23 toedieningen; jaar 2 en 3: 13 toedieningen. Maximale behandelduur van 36 maanden. Expected patient volume per year Patient volume < 133 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NKR 2018(1); Pakketadvies daratumumab (2); Additional remarks Jaarlijks aantal nieuwe multipel myeloom patiënten bedraagt 1.333 (1). Hiervan is 10% asymptomatisch (2). Dit betekent dat er maximaal 133 patiënten in aanmerking zullen komen voor deze behandeling. Expected cost per patient per year Cost € < 100,571.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Fabrikant, G-standaard Additional remarks Jaar 1: €100.571; Jaar 2 en 3: €56.845. Op basis van de lijstprijs. Potential total cost per year Total cost € 13,375,943.00 Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks